Galderma, the Swiss dermatology company, agreed on October 14, 2026 to buy US skincare brand ZO Skin Health for $1.5 billion in cash, buying it from private equity firm Blackstone and the Obagi family. Here is what the headlines confirm, what is still unknown, and exactly what a holder of Galderma or related names can check right now.
What did Galderma announce on October 14, 2026?
On October 14, 2026, Galderma agreed to buy US skincare firm ZO Skin Health for $1.5 billion in cash. The seller is private equity giant Blackstone together with the Obagi family, according to reports from Seeking Alpha, Dow Jones and Investing citing Reuters.
The deal was first detected in the early hours of October 14, 2026, around 06:15 UTC, and has been corroborated by three independent newsrooms. The core facts are consistent across all of them:
- Buyer: Galderma, the Swiss-listed dermatology company.
- Target: ZO Skin Health, a US skincare brand.
- Price: $1.5 billion, all cash.
- Sellers: Blackstone and the Obagi family.
Beyond those points, the published headlines do not yet spell out the full terms. That gap matters, and we flag it plainly below rather than guess.
What is still unknown about the Galderma ZO Skin Health deal?
Several details that investors usually want are not confirmed by the current headlines. Treating them as known would be inventing facts, so here is what remains open:
- Timing and closing conditions: no expected close date or regulatory-approval schedule has been reported.
- Financing: the deal is described as cash, but how Galderma funds it, from existing cash, new debt or otherwise, is not stated.
- Financials of ZO Skin Health: revenue, margins and earnings contribution are not disclosed in these headlines.
- Strategic rationale: management commentary beyond the purchase itself is not yet quoted.
When a story is only hours old, honest uncertainty beats false precision. Expect a formal release and possibly an investor call to fill these gaps in the coming days.
Who are the parties in this acquisition?
The deal connects a Swiss listed company, a US skincare brand and a global private equity firm. Here is a quick reference based only on what the headlines establish.
| Party | Role in deal | What the headlines say |
|---|---|---|
| Galderma | Buyer | Swiss dermatology company acquiring ZO Skin Health |
| ZO Skin Health | Target | US skincare firm being bought for $1.5B |
| Blackstone | Seller | Private equity firm exiting its stake |
| Obagi family | Co-seller | Selling alongside Blackstone |
Galderma trades in Swiss francs (CHF) on its home market, which matters if you hold it from a different currency base. Blackstone is listed separately in the US as BX, though a $1.5 billion disposal is small relative to its overall scale.
What does a $1.5 billion cash deal mean mechanically?
An all-cash acquisition means Galderma pays $1.5 billion and receives ownership of ZO Skin Health, with no new Galderma shares issued to the sellers as part of the headline terms. For a holder, that has a few plain mechanical implications.
- No automatic dilution from a share-based payment, based on what is reported so far.
- Cash leaves the balance sheet or new financing is taken on, which the full release should clarify.
- ZO Skin Health's results would eventually consolidate into Galderma once the deal closes.
None of this tells you what the share price will do. Markets price deals on perceived value, financing and strategic fit, and that reaction can take days to settle as more terms emerge.
How can a PortfolioTrackr user check their exposure right now?
Start by confirming whether you actually hold any name touched by this deal, and in what size. The fastest way is to look at your real exposure rather than your memory of it.
Check what you hold
Open your holdings and search for Galderma and, if relevant, Blackstone (BX). If you track positions across more than one account, the ALL PORTFOLIOS combined view, available on every plan for anyone with more than one portfolio, shows your total position in a single name in one place.
- See the weight of Galderma as a share of your total portfolio.
- Check whether you hold it directly or through a fund or ETF with Swiss-equity exposure.
- Review your cost and current value side by side.
If you hold a Swiss-listed share from, say, a US-dollar or sterling base, your currency line matters. PortfolioTrackr converts the cost of a holding at the exchange rate of the day you bought it and its value at today's rate, then shows the currency gain or loss as its own line on the summary card and the P&L chart. That separates the business story from the CHF move, which is easy to confuse during a news spike. Our guide on tracking stocks and crypto together in one app walks through the same multi-currency logic.
Set a price alert on your own level
If you want to know when Galderma trades through a level that matters to you, set a price alert. PortfolioTrackr checks every position and every watchlist level once a minute while the market is open, and around the clock for crypto, so you hear within a minute of your level being hit.
- Set Target 1, Target 2 or a stop-loss level on the position itself.
- Add a price above or price below on a watchlist entry if you are only watching, not holding.
- Receive the alert by email, WhatsApp, Telegram or push on every plan, with SMS on Pro and Lifetime.
These are price levels only. PortfolioTrackr reports status against your own numbers, such as still below target or Target 1 reached, and does not tell you what to do with the position. The decision stays yours.
How should you think about a foreign listing like Galderma?
Galderma is a Swiss stock, so for many readers it is a foreign holding with a currency layer on top of the business. That layer can flatter or mask a move in the shares themselves.
PortfolioTrackr supports 100 stock exchanges and 100 currencies for display and conversion, with 10 years of daily exchange rates behind the P&L. So when Galderma moves on this news, you can see how much of your gain or loss is the share and how much is the CHF rate against your base currency.
If you are weighing whether an app beats a spreadsheet for this kind of multi-currency, multi-market tracking, our portfolio tracker versus spreadsheet comparison lays out where each one struggles. For connecting an account automatically, the walkthrough on how to connect your brokerage account covers the options, though manual entry, CSV, voice and screenshot import always work on every plan.
What should investors watch next?
With the deal only hours old, the next few days should supply the detail the first headlines left out. Here is a plain checklist of what to watch, stated as facts to confirm, not actions to take.
- The official Galderma release and any investor presentation with full terms.
- How Galderma says it will fund the $1.5 billion, cash on hand or new debt.
- Any regulatory or antitrust steps and an expected close date.
- Disclosed revenue or earnings contribution from ZO Skin Health.
- Any Blackstone commentary, given it is the selling party.
- The share price reaction once Zurich trades fully digest the news.
For context on how other deal and corporate-event stories have played out for holders, our breakdown of what the CSG stake in MDA Space means for holders follows the same what-happened, what-is-unknown, what-to-check structure.
The bottom line
On October 14, 2026, Galderma agreed to buy ZO Skin Health for $1.5 billion in cash from Blackstone and the Obagi family. That much is confirmed by three newsrooms; the financing, timing and financial detail are not yet public, so treat anything beyond the headline terms as pending.
What you can do right now is factual, not speculative: confirm whether you hold Galderma or Blackstone, check the position's weight and currency line, and set a price alert on a level you care about so you hear within a minute if it is hit. The news is Galderma's to deliver next; your exposure is yours to understand today.
Track your portfolio in real time: free for 3 days
Live P&L across stocks, crypto, and global markets. WhatsApp and Telegram price alerts. AI trade import. Unified dividend tracking. No brokerage connection required.
Start Free Trial
Frequently asked questions
How much is Galderma paying for ZO Skin Health?
Galderma agreed to pay $1.5 billion in cash for ZO Skin Health, announced on October 14, 2026. The sellers are private equity firm Blackstone and the Obagi family. The full financing structure and closing timeline were not detailed in the first headlines.
Who is selling ZO Skin Health to Galderma?
Blackstone, the global private equity firm, is selling ZO Skin Health alongside the Obagi family. The headlines confirm both parties as sellers in the $1.5 billion all-cash transaction, though neither party's specific stake size was disclosed in the initial reports on October 14, 2026.
Will the Galderma deal dilute existing shareholders?
Based on the reported terms, the deal is all cash rather than stock, so no new Galderma shares are issued to the sellers as part of the headline price. Whether Galderma funds it from cash or new debt is not yet confirmed and should appear in the full release.
How do I track my Galderma exposure in a different currency?
PortfolioTrackr converts a holding's cost at the exchange rate of your purchase date and its value at today's rate, showing the currency gain or loss as its own line. Galderma trades in Swiss francs, so this separates the share move from the CHF move for non-CHF investors.
Can I get an alert if Galderma hits a price level?
Yes. PortfolioTrackr lets you set Target 1, Target 2 or a stop-loss level on a position, or a price above or below on a watchlist. It checks once a minute while the market is open and alerts you within a minute of your level being hit, by email, WhatsApp, Telegram or push.